Share-based Payment Arrangement, Expense of Cue Biopharma, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cue Biopharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • Cue Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,533,000, a 3.2% decline year-over-year.
  • Cue Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,696,000, a 23% decline year-over-year.
  • Cue Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,846,000, a 16% decline from 2023.
  • Cue Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,180,000, a 86042% increase from 2022.
  • Cue Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,496, a 100% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cue Biopharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,696,000 $1,533,000 -$50,000 -3.2% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $5,746,000 $1,263,000 -$492,000 -28% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $6,238,000 $1,338,000 -$608,000 -31% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $6,846,000 $1,562,000 -$510,000 -25% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $7,356,000 $1,583,000 -$490,000 -24% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $7,846,000 $1,755,000 -$282,000 -14% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $8,128,000 $1,946,000 -$52,000 -2.6% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $8,180,000 $2,072,000 +$9,446,504 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $1,266,504 $2,073,000 +$9,000 +0.44% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,275,504 $2,037,000 -$272,000 -12% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $1,003,504 $1,998,000 -$1,013,000 -34% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $9,496 $7,374,504 -$10,348,088 -348% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $10,357,584 $2,064,000 -$1,188,000 -37% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $11,545,584 $2,309,000 -$545,000 -19% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $12,090,584 $3,011,000 +$575,000 +24% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $11,515,584 $2,973,584 +$691,802 +30% 01 Oct 2021 31 Dec 2021 10-K 21 Mar 2023 2022 FY
Q3 2021 $10,823,782 $3,252,000 +$752,000 +30% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $10,071,782 $2,854,000 +$330,000 +13% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $9,741,782 $2,436,000 -$739,000 -23% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $10,480,782 $2,281,782 +$288,800 +14% 01 Oct 2020 31 Dec 2020 10-K 16 Mar 2022 2021 FY
Q3 2020 $10,191,982 $2,500,000 +$1,061,000 +74% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $9,130,982 $2,524,000 +$1,203,000 +91% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $7,927,982 $3,175,000 +$1,407,000 +80% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $6,520,982 $1,992,982 -$16,731 -0.83% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $6,537,713 $1,439,000 -$1,292,000 -47% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $7,829,713 $1,321,000 +$46,000 +3.6% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $7,783,713 $1,768,000 +$610,000 +53% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $7,173,713 $2,009,713 +$1,235,350 +160% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $5,938,363 $2,731,000 +$1,980,000 +264% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $3,958,363 $1,275,000 +$568,000 +80% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $3,390,363 $1,158,000 +$615,000 +113% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $2,775,363 $774,363 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q3 2017 $751,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $707,000 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018 2018 Q2
Q1 2017 $543,000 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1

Cue Biopharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,846,000 -$1,334,000 -16% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $8,180,000 +$8,170,504 +86042% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $9,496 -$11,506,088 -100% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $11,515,584 +$1,034,802 +9.9% 01 Jan 2021 31 Dec 2021 10-K 21 Mar 2023 2022 FY
2020 $10,480,782 +$3,959,800 +61% 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022 2021 FY
2019 $6,520,982 -$652,731 -9.1% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $7,173,713 +$4,398,350 +158% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $2,775,363 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.